Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (161-170 of 193) with videos related to

Pageof 20
Sort By:
Hematological Oncology|January 14, 2025
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life ExperienceIdanna Innocenti, Annamaria Tomasso, Diana Giannarelli, et al.
Therapeutic Advances in Hematology|October 17, 2022
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemiaAnna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, et al.
British Journal of Haematology|February 16, 2023
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literatureIlaria Del Giudice, Luca Vincenzo Cappelli, Julio Delgado, et al.
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Blood Advances|June 12, 2025
Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control StudyAlberto Fresa, Idanna Innocenti, Annamaria Tomasso, et al.
Hemasphere|December 2, 2024
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experienceIdanna Innocenti, Antonio Mosca, Annamaria Tomasso, et al.
American Journal of Hematology|November 9, 2022
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" studyShai Levi, Yotam Bronstein, Neta Goldschmidt, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Pageof 20

Showing results (161-170 of 193) with videos related to

Sort By:
Pageof 20
Hematological Oncology|January 14, 2025
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life ExperienceIdanna Innocenti, Annamaria Tomasso, Diana Giannarelli, et al.
Therapeutic Advances in Hematology|October 17, 2022
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemiaAnna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, et al.
British Journal of Haematology|February 16, 2023
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literatureIlaria Del Giudice, Luca Vincenzo Cappelli, Julio Delgado, et al.
Leukemia|June 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomesSara Pepe, Candida Vitale, Diana Giannarelli, et al.
Blood Cancer Journal|July 19, 2022
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian studyLivio Pagano, Marianna Criscuolo, Alessandro Broccoli, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Blood Advances|June 12, 2025
Familial Forms of Chronic Lymphocytic Leukemia Have a Worse Prognosis Than Sporadic Forms: an Italian Case-Control StudyAlberto Fresa, Idanna Innocenti, Annamaria Tomasso, et al.
Hemasphere|December 2, 2024
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experienceIdanna Innocenti, Antonio Mosca, Annamaria Tomasso, et al.
American Journal of Hematology|November 9, 2022
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" studyShai Levi, Yotam Bronstein, Neta Goldschmidt, et al.
Hemasphere|July 16, 2024
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experienceRiccardo Bomben, Antonella Zucchetto, Roberta Laureana, et al.
Pageof 20